Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset

Download Results

Project # Sort ascending	Project Title	Research Focus Area	Research Program	Administering IC	Institution(s)	Investigator(s)	Location(s)	Year Awarded
R41DA055405-01	Virtual Reality Facilitation of Recovery from Opioid Use Disorder	Cross-Cutting Research	Small Business Programs	NIDA	Relate XR LLC	OBERLIN, BRANDON G (contact); NELSON, ANDREW	Indianapolis, IN	2022
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) NOFO Number: RFA-DA-19-020 Summary: Relapse is common in people with opioid use disorder, and recovery attempts often fail within 6 months. This research project will test a novel virtual reality intervention to improve recovery outcomes for people recovering from opioid use disorder. By increasing future orientation and delay-of-reward behavior with a precision medicine personalized experience, the intervention is designed to enhance advantageous decision-making and increase positive future outcomes. The results of this study will provide critical data for creating a commercially viable software product for facilitating relapse prevention and improving opioid use disorder recovery outcomes.
R24DA055306-01	Wake Forest IMPOWR Dissemination Education and Coordination Center (IDEA-CC)			NIDA	Wake Forest University Health Sciences	ADAMS, MEREDITH C B	Winston-Salem, NC	2022
NOFO Title: Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data NOFO Number: NOT-OD-22-067 Summary: This research is intended to create multidisciplinary team science collaborations to develop effective interventions, best models of care for delivery of services, and sustainable implementation strategies for access to quality care for complex patients with chronic pain and opioid use disorder or opioid misuse. To allow comparison and analysis of data created in nine unique clinical trials funded across four centers, common data elements (CDEs) were selected to assess all aspects of a patient’s condition and experience. The purpose of this project is to make the IMPOWR CDE data more FAIR (Findable, Accessible, Interoperable, Reusable) by building a tool that will automate the mapping/conversion of HEAL-related data to the Observational Medical Outcomes Partnership data model that allows for systematic analysis of data from different databases. Upon completion, this tool would be shared with the HEAL research community as a new resource to enable broader harmonization and secondary data analysis.
9SB1NS137964-04	Advancing precision pain medicines to the clinic	Cross-Cutting Research	Small Business Programs	NINDS	NAVEGA THERAPEUTICS, INC.	MORENO, ANA MARIA (contact); ALEMAN GUILLEN, FERNANDO	San Diego, CA	2023
NOFO Title: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) NOFO Number: PAR-23-069
9R42NS120548-02A1	Development of KLS-13019 for Neuropathic Pain	Cross-Cutting Research	Small Business Programs	NINDS	KANNALIFE SCIENCES, INC.	BRENNEMAN, DOUGLAS ERIC (contact); WARD, SARA J	Lloyd Harbor, NY	2021
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) NOFO Number: RFA-NS-20-009 Summary: Neuropathic pain adversely affects quality of life and remains challenging to treat, presenting high unmet medical need. One example of this type of pain, chemotherapy-induced peripheral neuropathy, is a chronic, severely debilitating consequence of cancer therapy for which there are no effective treatment strategies. This research is testing a new cannabidiol (CBD) analogue (KLS-13019) with neuroprotective properties and which has improved drug-like properties compared to CBD. This project will optimize the process to manufacture KLS-13019, develop analytical methods, optimize its formulation, evaluate its safety and toxicity, and test KLS-13019’s efficacy of in a rat model of chemotherapy-induced peripheral neuropathy.
75N95019D00013-P00002-759502000002-1	Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy	New Strategies to Prevent and Treat Opioid Addiction	Optimizing the Duration, Retention, and Discontinuation of Medication Treatment for Opioid Use Disorder	NIDA	Emmes Corportation	VanVeldhuisen, Paul	Rockville, MD	2019
NOFO Number: Summary: This study will (1) test pharmacologic and behavioral strategies to improve OUD pharmacotherapy treatment retention and to improve outcomes among patients who have been successfully stabilized on OUD medications and want to stop medication and (2) identify predictors of successful outcome and develop a stage model of relapse risk.